JMP Securities Reiterates a Hold Rating on OrthofixBy Ryan Adsit
According to TipRanks.com, Turkaly is a 4-star analyst with an average return of 13.8% and a 57.6% success rate. Turkaly covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Integra Lifesciences, and Orasure Technologies.
Orthofix has an analyst consensus of Hold.
Based on Orthofix’s latest earnings report from June 30, the company posted quarterly revenue of $104.1M and quarterly net profit of -$7.39M. In comparison, last year the company earned revenue of $101.2M and had a net profit of -$1.37M.
Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is negative on the stock. Most recently, in September 2016, Michael Finegan, the CSO of OFIX sold 25,000 shares for a total of $1,129,000.
Orthofix International NV is engaged in the research, development, and market of orthopedic solutions. It operates through the following business segments: BioStim, Biologics, Extremity Fixation, and Spine Fixation. The BioStim segment produces and sells devices for bone fusion enhancement in cervical and lumbar spine through the pulsed electromagnetic technology. The Biologics segment includes regenerative products. The Extremity Fixation segment manufactures and distributes orthopedic products for fracture repair, deformity correction, and bone reconstruction. The Spine Fixation segment develops and sells implant products for spine surgeries. The company was founded on October 19, 1987 and is headquartered in Willemstad, Netherlands.